Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of late clinical events after drug-eluting versus bare-metal stents in patients at risk: BAsel Stent Kosten Effektivitats Trial - PROspective Validation Examination

Next Previous
X
Search
Trial Profile

Evaluation of late clinical events after drug-eluting versus bare-metal stents in patients at risk: BAsel Stent Kosten Effektivitats Trial - PROspective Validation Examination

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Dec 2015

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Sirolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms BASKET-PROVE

    • Most Recent Events

    • 17 Jul 2015 Results of pre-specified subgroup analysis (n = 405/2314; aged greater than or equal to 75 years) published in the American Heart Journal.
    • 31 Aug 2011 Results of a priori-planned analysis of the effects of renal function on treatment outcomes presented at the ESC Congress 2011: Annual Congress of the European Society of Cardiology.
    • 31 Aug 2011 Results of a priori-planned gender-specific analysis presented at the ESC Congress 2011: Annual Congress of the European Society of Cardiology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top